Know Cancer

or
forgot password

Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia


Phase 2
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia


Inclusion Criteria:



- breast cancer patient treated with adjuvant chemotherapy

- PS = 2 or less

Exclusion Criteria:

- none

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Outcome Measure:

Prevention of myelotoxicity-every week during chemotherapy.

Principal Investigator

Georgeta Fried, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rambam Health Care Campus

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

LifemelCTIL

NCT ID:

NCT00243165

Start Date:

November 2005

Completion Date:

Related Keywords:

  • Breast Cancer
  • breast cancer
  • honey
  • myelosuppression
  • chemotherapy
  • Breast Neoplasms
  • Leukopenia

Name

Location